Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adult Hematopoietic Cell Transplant Recipients: A Single Center Study

Hematopoietic cell transplant (HCT) recipients are at high risk for Varicella zoster virus (VZV) reactivation. Shingrix, the adjuvanted recombinant zoster vaccine, is a new alternative to the live-attenuated VZV vaccine for immunocompromised individuals. Post-marketing data on its immunogenicity and safety in HCT is limited.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Jose F. Camargo, Rick Y Lin, Anthony D. Anderson, Lisy Crucet, Maritza C. Alencar, Trent P. Wang, Michele I. Morris, Krishna V. Komanduri Tags: 509 Source Type: research